Publicaciones en colaboración con investigadores/as de Hospital Clinico Universitario de Valencia (51)

2024

  1. Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain

    AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314

  2. Bictegravir/emtricitabine/tenofovir alafenamide as first-line treatment in naïve HIV patients in a rapid-initiation model of care: BIC-NOW clinical trial

    International Journal of Antimicrobial Agents, Vol. 63, Núm. 6

  3. Monkeypox virus genomic accordion strategies

    Nature Communications, Vol. 15, Núm. 1

  4. Real-life data of immune recovery using bictegravir/emtricitabine/ tenofovir alafenamide in virologically suppressed people living with HIV. Results at 48–96 weeks of RETROBIC Study

    Journal of Antimicrobial Chemotherapy, Vol. 79, Núm. 3, pp. 595-607

2023

  1. Hydroxychloroquine and Mortality in SARS-Cov-2 Infection; the HOPE-Covid-19 Registry

    Anti-Infective Agents, Vol. 21, Núm. 2, pp. 66-78

  2. Mortality reduction in older COVID-19-patients hospitalized in Spain during the second pandemic wave from the SEMI-COVID-19 Registry

    Scientific Reports, Vol. 13, Núm. 1

2022

  1. Chronic Oral Anticoagulation Therapy and Prognosis of Patients Admitted to Hospital for COVID-19: Insights from the HOPE COVID-19 Registry

    International Journal of Clinical Practice, Vol. 2022

  2. Discovering HIV related information by means of association rules and machine learning

    Scientific Reports, Vol. 12, Núm. 1

  3. Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019

    HIV Medicine, Vol. 23, Núm. 7, pp. 705-716

  4. Predictors of poor prognosis in healthy, young, individuals with SARS-CoV-2 infections

    Clinical Microbiology and Infection, Vol. 28, Núm. 2, pp. 273-278

  5. Progress in the quality of care for newly diagnosed people with HIV in Spain (2004–2019)

    Antiviral Therapy, Vol. 27, Núm. 4

  6. Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish Cohort

    Infectious Diseases and Therapy, Vol. 11, Núm. 3, pp. 1177-1192

2021

  1. Association between long term exposure to particulate matter and incident hypertension in Spain

    Scientific Reports, Vol. 11, Núm. 1

  2. Fatty liver index as a predictor for type 2 diabetes in subjects with normoglycemia in a nationwide cohort study

    Scientific Reports, Vol. 11, Núm. 1

  3. Impact of smoking on COVID-19 outcomes: A HOPE Registry subanalysis

    BMJ Nutrition, Prevention and Health, Vol. 4, Núm. 1, pp. 285-292

  4. Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-19 registry

    Internal and Emergency Medicine, Vol. 16, Núm. 4, pp. 957-966

  5. Real world effectiveness of standard of care triple therapy versus two-drug combinations for treatment of people living with HIV

    PloS one, Vol. 16, Núm. 4, pp. e0249515

  6. Redefining therapeutic success in HIV patients: An expert view

    Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 10, pp. 2501-2518

  7. Sepsis of Patients Infected by SARS-CoV-2: Real-World Experience From the International HOPE-COVID-19-Registry and Validation of HOPE Sepsis Score

    Frontiers in Medicine, Vol. 8

  8. Underlying heart diseases and acute covid-19 outcomes

    Cardiology Journal, Vol. 28, Núm. 2, pp. 202-214